Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccination
Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy
No previous vaccination with a pneumococcal vaccine
Subject or parent/legal guardian able to complete an electronic diary
You may not be if
Acquired immune deficiency syndrome (AIDS) at time of enrollment
Current illicit substance and/or alcohol abuse
History of active chronic viral hepatitis
Previous anaphylactic reaction to a vaccine or vaccine-related component
Serious chronic disorders including metastatic malignancy and end-stage renal disease
Clareo Health | Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
